Murat Iskar

7PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMicro- and nanosystemsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 07, 2025
Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.

L Llaó-Cid, Jkl Wong, I Fernandez Botana

|Jan 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast

|May 30, 2024
Systematic assessment of ISWI subunits shows that NURF creates local accessibility for CTCF.

Mario Iurlaro, Francesca Masoni, Ilya M Flyamer

|Oct 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Sophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt

|Jul 30, 2017
Tumor-derived exosomes modulate PD-L1 expression in monocytes.

Franziska Haderk, Ralph Schulz, Murat Iskar

|Nov 23, 2016
The endosomal transcriptional regulator RNF11 integrates degradation and transport of EGFR.

Sandra Scharaw, Murat Iskar, Alessandro Ori

Pageof 2

Frequent Collaborators

4 joint publications

Marc Zapatka

3 joint publications

Martina Seiffert

3 joint publications

Sascha Dietrich

2 joint publications

Laura Llaó Cid